Portage Biotech (NASDAQ: PRTG) has made some serious waves recently, with its stock skyrocketing 131%. This surge resulted in a $9.0 million bump to the company’s market cap, from just $2.15 million to $5.03 million.

This sudden spike has insiders smiling, and here’s why it matters for you as an investor.

In the past year, insiders, those people closest to the company, made significant moves, buying up shares. The biggest purchase came from Gregory Bailey, Portage’s Independent Lead Director, who bought $1.6 million worth of stock at $4.10 a share.

Fast forward to today, and those shares are worth much more. While we can’t always rely on insider moves to make decisions, it’s still a strong signal that those in the know believe in Portage’s future.

Tumor-Fighting Revolution

But it’s not just about insiders buying shares, Portage Biotech is also making moves in cancer treatment.

The company recently presented groundbreaking preclinical data at the 2025 European Lung Cancer Congress. Their drug, PORT-7, showed a massive 90% inhibition of tumor growth in mesothelioma, a tough cancer to treat. This drug could be the next big thing in cancer immunotherapy.

Portage is preparing for its first human trial of PORT-7. If these results hold up, it could change the game for cancer treatments. Alongside this, they’re also testing another drug, PORT-6, in combination with PORT-7 to create a powerful one-two punch against tumors.

Next Rising Star

So, what does this all mean for investors? Portage Biotech’s stock might just be heating up. With insiders buying, promising preclinical results, and an upcoming human trial, the company is on track for a potentially huge breakthrough in immuno-oncology.

If you’re looking for a small-cap biotech with big potential, Portage might be one to keep an eye on.